State Street Corp boosted its holdings in Savara Inc (NASDAQ:SVRA) by 1.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 554,551 shares of the company’s stock after buying an additional 6,802 shares during the period. State Street Corp owned approximately 1.06% of Savara worth $1,176,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Citigroup Inc. increased its position in Savara by 176.8% in the 4th quarter. Citigroup Inc. now owns 11,358 shares of the company’s stock worth $51,000 after buying an additional 7,255 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Savara by 10.7% during the 1st quarter. Bank of New York Mellon Corp now owns 78,099 shares of the company’s stock worth $166,000 after purchasing an additional 7,577 shares in the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of Savara during the 4th quarter worth approximately $39,000. Jane Street Group LLC acquired a new stake in shares of Savara during the 4th quarter worth approximately $49,000. Finally, Metropolitan Life Insurance Co NY acquired a new stake in shares of Savara during the 1st quarter worth approximately $83,000. 46.02% of the stock is currently owned by institutional investors.
Shares of SVRA stock opened at $2.70 on Wednesday. The stock’s fifty day simple moving average is $2.52 and its 200 day simple moving average is $2.52. The company has a debt-to-equity ratio of 0.28, a current ratio of 13.90 and a quick ratio of 13.90. The firm has a market cap of $143.51 million, a price-to-earnings ratio of -1.45 and a beta of 0.92. Savara Inc has a one year low of $0.69 and a one year high of $5.48.
Several brokerages have recently weighed in on SVRA. Zacks Investment Research lowered Savara from a “buy” rating to a “hold” rating in a report on Wednesday, June 10th. HC Wainwright reissued a “buy” rating on shares of Savara in a report on Tuesday, March 17th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Savara currently has an average rating of “Buy” and an average target price of $6.69.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
See Also: What is the QQQ ETF?
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.